RARE

26.30

0.69% 0.18

Pre-mercato: 26.25 -0.05 -0.19%

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RARE Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$26.12

Aprire:

$26.45

Volume 24 ore:

1.71M

Relative Volume:

0.85

Capitalizzazione di mercato:

$2.59B

Reddito:

$672.72M

Utile/perdita netta:

$-575.44M

Rapporto P/E:

-4.5064

EPS:

-5.8361

Flusso di cassa netto:

$-487.00M

1 W Prestazione:

+6.01%

1M Prestazione:

+12.88%

6M Prestazione:

-20.90%

1 anno Prestazione:

-25.09%

Intervallo 1D:

$26.21

$27.42

Intervallo di 1 settimana:

$24.23

$27.42

Portata 52W:

$18.29

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Nome

Ultragenyx Pharmaceutical Inc

Settore

Healthcare (1110)

Industria

Biotechnology (619)

Telefono

415-483-8800

Indirizzo

60 LEVERONI COURT, NOVATO, CA

Dipendente

1,371

Cinguettio

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RARE Ultragenyx Pharmaceutical Inc	26.30	2.57B	672.72M	-575.44M	-487.00M	-5.8361
VRTX Vertex Pharmaceuticals Inc	435.17	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	712.77	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	813.28	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	284.84	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	310.75	32.38B	5.36B	287.73M	924.18M	2.5229

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-24	Downgrade	Goldman	Buy → Neutral
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-07-28	Ripresa	H.C. Wainwright	Buy
2025-05-28	Iniziato	William Blair	Outperform
2024-06-06	Aggiornamento	Goldman	Neutral → Buy
2024-04-22	Iniziato	RBC Capital Mkts	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-06-06	Aggiornamento	Evercore ISI	In-line → Outperform
2023-04-26	Iniziato	Cantor Fitzgerald	Overweight
2023-01-18	Ripresa	Canaccord Genuity	Buy
2022-12-30	Ripresa	H.C. Wainwright	Buy
2022-11-03	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-01	Downgrade	Evercore ISI	Outperform → In-line
2022-03-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2022-02-11	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-30	Iniziato	H.C. Wainwright	Buy
2021-08-19	Iniziato	UBS	Sell
2021-07-15	Iniziato	Guggenheim	Neutral
2021-06-29	Aggiornamento	BofA Securities	Neutral → Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	Citigroup	Neutral → Buy
2021-05-06	Aggiornamento	Evercore ISI	In-line → Outperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-02	Ripresa	Stifel	Buy
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-07	Downgrade	Wedbush	Outperform → Neutral
2020-11-24	Ripresa	Evercore ISI	In-line
2020-11-12	Downgrade	BofA Securities	Buy → Neutral
2019-08-02	Ripresa	Wedbush	Outperform
2019-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-08	Aggiornamento	Citigroup	Sell → Neutral
2018-09-10	Iniziato	Morgan Stanley	Equal-Weight
2018-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2018-05-11	Aggiornamento	Barclays	Equal Weight → Overweight
2018-05-10	Iniziato	Goldman	Neutral
2018-04-18	Aggiornamento	SunTrust	Hold → Buy
2018-03-22	Ripresa	Piper Jaffray	Overweight
2018-02-21	Reiterato	Stifel	Buy
2018-01-22	Aggiornamento	Evercore ISI	In-line → Outperform
2018-01-18	Iniziato	Credit Suisse	Outperform
2017-12-05	Reiterato	Barclays	Equal Weight
2017-12-04	Aggiornamento	Jefferies	Hold → Buy
2017-09-14	Aggiornamento	Wedbush	Neutral → Outperform

Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

May 11, 2026

GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News

May 11, 2026

Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa

May 11, 2026

Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com Nigeria

May 11, 2026

Number of shareholders of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView

May 11, 2026

Number of shareholders of Ultragenyx Pharmaceutical, Inc. – FWB:UP0 - TradingView

May 11, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Strong Sell" at Wall Street Zen - MarketBeat

May 11, 2026

Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses? - Yahoo Finance

May 11, 2026

May 10, 2026

RARE SEC FilingsUltragenyx Pharm 10-K, 10-Q, 8-K Forms - Stock Titan

May 10, 2026

Vanguard Group Inc. Buys 131,087 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

May 10, 2026

May 09, 2026

Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo

May 09, 2026

Ultragenyx Pharmaceutical (RARE) Is Up 5.8% After Reaffirming 2026 Outlook Despite Wider Losses – What's Changed - Sahm

May 09, 2026

Guggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat

May 08, 2026

May 07, 2026

Ultragenyx to Present at Bank of America Healthcare Conference on May 13, 2026 - geneonline.com

May 07, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript - Insider Monkey

May 07, 2026

Rare disease families find roadmap to drug development at bootcamps - CNBC

May 07, 2026

Ultragenyx Pharmaceutical (RARE) Heavy Q1 EPS Loss Tests Bulls Profitability Timeline Narrative - Sahm

May 07, 2026

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $35 - Moomoo

May 07, 2026

May 06, 2026

Ultragenyx Earnings Call: Growth, Gene Therapy and Risk - TipRanks

May 06, 2026

Ultragenyx Pharmaceutical Inc. 2024 SEC Filing: Financial Information, Forward-Looking Statements, and Market Risks - Minichart

May 06, 2026

Ultragenyx investors can watch CFO at Bank of America panel May 12 - Stock Titan

May 06, 2026

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference - The Manila Times

May 06, 2026

Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com India

May 06, 2026

Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares By Investing.com - Investing.com South Africa

May 06, 2026

Ultragenyx (NASDAQ: RARE) CMO sells shares to cover RSU taxes - Stock Titan

May 06, 2026

Ultragenyx outlines $730M-$760M 2026 revenue as it targets two gene therapy PDUFAs in August and September - MSN

May 06, 2026

RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect - Yahoo Finance

May 06, 2026

Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

May 06, 2026

Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan

May 06, 2026

Wedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

May 06, 2026

Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 06, 2026

Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

May 06, 2026